<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The brain renin-angiotensin system plays a crucial role in regulating body weight in dietinduced obesity in rats</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Ph.D</roleName><forename type="first">Walter</forename><surname>Raasch</surname></persName>
							<email>walter.raasch@pharma.uni-luebeck.de</email>
							<affiliation key="aff1">
								<orgName type="department">Institute of Experimental and Clinical Pharmacology and Toxicology</orgName>
								<orgName type="institution">University of Lübeck</orgName>
								<address>
									<settlement>Lübeck, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="laboratory">DZHK (German Centre for Cardiovascular Research)</orgName>
								<address>
									<addrLine>partner site Hamburg</addrLine>
									<settlement>Kiel, Lübeck, Lübeck, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">CBBM (Center of Brain, Behavior and Metabolism)</orgName>
								<address>
									<settlement>Lübeck</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martina</forename><surname>Winkler</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Experimental and Clinical Pharmacology and Toxicology</orgName>
								<orgName type="institution">University of Lübeck</orgName>
								<address>
									<settlement>Lübeck, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johanna</forename><surname>Schuchard</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Experimental and Clinical Pharmacology and Toxicology</orgName>
								<orgName type="institution">University of Lübeck</orgName>
								<address>
									<settlement>Lübeck, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="laboratory">DZHK (German Centre for Cardiovascular Research)</orgName>
								<address>
									<addrLine>partner site Hamburg</addrLine>
									<settlement>Kiel, Lübeck, Lübeck, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ines</forename><surname>Stölting</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Experimental and Clinical Pharmacology and Toxicology</orgName>
								<orgName type="institution">University of Lübeck</orgName>
								<address>
									<settlement>Lübeck, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Florian</forename><forename type="middle">M V</forename><surname>Ogt</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department for Radiology and Nuclear Medicine</orgName>
								<orgName type="institution">University of Lübeck</orgName>
								<address>
									<settlement>Lübeck, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jörg</forename><surname>Barkhausen</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department for Radiology and Nuclear Medicine</orgName>
								<orgName type="institution">University of Lübeck</orgName>
								<address>
									<settlement>Lübeck, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Thorns</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">University Clinic Schleswig-Holstein</orgName>
								<address>
									<addrLine>Campus Lübeck</addrLine>
									<settlement>Lübeck, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Bader</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Max-Delbrück-Center for Molecular Medicine (MDC)</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="laboratory">DZHK (German Centre for Cardiovascular Research)</orgName>
								<address>
									<addrLine>partner site Berlin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Center for Structural and Cell Biology in Medicine</orgName>
								<orgName type="department" key="dep2">Institute for Biology</orgName>
								<orgName type="institution">University of Lübeck</orgName>
								<address>
									<settlement>Lübeck, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="institution">Charité -University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Institute of Experimental and Clinical Pharmacology and Toxicology</orgName>
								<orgName type="institution">University of Lübeck</orgName>
								<address>
									<addrLine>Ratzeburger Allee 160</addrLine>
									<postCode>23538</postCode>
									<settlement>Lübeck</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The brain renin-angiotensin system plays a crucial role in regulating body weight in dietinduced obesity in rats</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">A7EDBE3345FD01E05B6B0AFAA278B18F</idno>
					<idno type="DOI">10.1111/bph.13461</idno>
					<note type="submission">Received 28 July 2015; Revised 4 February 2016; Accepted 14 February 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>regulated transcript</term>
					<term>CD, cafeteria diet</term>
					<term>C max , maximal concentration</term>
					<term>EE, energy expenditure</term>
					<term>GFAP , glial fibrillary acidic protein</term>
					<term>HDL, high-density lipoproteins</term>
					<term>HOMA, Homeostatic model assessment index</term>
					<term>HP A axis, hypothalamic-pituitary-adrenal axis</term>
					<term>LRT, leptin resistance test</term>
					<term>OGTT, oral glucose tolerance test</term>
					<term>POMC, proopiomelanocortin</term>
					<term>RAS, renin-angiotensin system</term>
					<term>RER, respiratory exchange rate</term>
					<term>SBP , systolic blood pressure</term>
					<term>SD, Sprague Dawley rat</term>
					<term>TG, transgenic rat</term>
					<term>T2DM, type 2 diabetes mellitus</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BACKGROUND AND PURPOSE</head><p><s>Reduced weight gain after treatment with AT 1 receptor antagonists may involve a brain-related mechanism.</s><s>Here, we investigated the role of the brain renin-angiotensin system on weight regulation and food behaviour, with or without additional treatment with telmisartan.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head><p><s>Transgenic rats with a brain-specific deficiency in angiotensinogen (TGR(ASrAOGEN)) and the corresponding wild-type, Sprague Dawley (SD) rats were fed (3 months) with a high-calorie cafeteria diet (CD) or standard chow.</s><s>SD and TGR(ASrAOGEN) rats on the CD diet were also treated with telmisartan (8 mg•kg À1 •d À1 , 3 months).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>Compared with SD rats, TGR(ASrAOGEN) rats (i) had lower weights during chow feeding, (ii) did not become obese during CD feeding, (iii) had normal baseline leptin plasma concentrations independent of the feeding regimen, whereas plasma leptin of SD rats was increased due to CD, (iv) showed a reduced energy intake, (v) had a higher, strain-dependent energy expenditure, which is additionally enhanced during CD feeding, (vi) had enhanced mRNA levels of pro-opiomelanocortin and (vii) showed improved glucose control.</s><s>Weight gain and energy intake in rats fed the CD diet were markedly reduced by telmisartan in SD rats but only to a minor extent in TGR(ASrAOGEN) rats.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSIONS</head><p><s>The brain renin-angiotensin system affects body weight regulation, feeding behaviour and metabolic disorders.</s><s>When angiotensin II levels are low in brain, rats are protected from developing diet-induced obesity and obesity-related metabolic impairments.</s><s>We further suggest that telmisartan at least partly lowers body weight via a CNS-driven mechanism.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>A number of AT 1 receptor antagonists such as candesartan, olmesartan or telmisartan have repeatedly been demonstrated to reduce body weight in lean <ref type="bibr" target="#b78">(Zorad et al., 2006;</ref><ref type="bibr" target="#b23">He et al., 2010;</ref><ref type="bibr" target="#b51">Müller-Fielitz et al., 2011)</ref> or obese rodents <ref type="bibr" target="#b64">(Schupp et al., 2005;</ref><ref type="bibr" target="#b23">He et al., 2010;</ref><ref type="bibr" target="#b40">Miesel et al., 2012;</ref><ref type="bibr" target="#b48">Müller-Fielitz et al., 2012a;</ref><ref type="bibr" target="#b71">V azquez-Medina et al., 2013;</ref><ref type="bibr" target="#b47">Müller-Fielitz et al., 2014;</ref><ref type="bibr" target="#b49">Müller-Fielitz et al., 2015;</ref><ref type="bibr" target="#b63">Schuchard et al., 2015)</ref>.</s><s>In patients, a moderate weight loss was also observed during irbesartan therapy <ref type="bibr" target="#b32">(Kintscher et al., 2007)</ref>.</s><s>In line with the findings after AT 1 receptor blockade, body weights of the double AT 1A /AT 1B receptor knockout (KO) mice were reduced <ref type="bibr" target="#b15">(Gembardt et al., 2008)</ref>, which strengthens the importance of these pharmacological insights into the effects of AT 1 receptor antagonists.</s></p><p><s>Considering the adipocyte-brain crosstalk that is known to be involved in regulating energy intake, energy expenditure and body weight, several mechanisms have been found to participate in weight loss induced by AT 1 receptor blockade.</s><s>These include peripheral-associated pathways such as a reduced growth of adipocytes <ref type="bibr" target="#b78">(Zorad et al., 2006;</ref><ref type="bibr" target="#b48">Müller-Fielitz et al., 2012a)</ref>, anti-inflammatory effects <ref type="bibr" target="#b5">(Cole et al., 2010;</ref><ref type="bibr" target="#b21">Guo et al., 2011)</ref> or the activation of PP AR-δ <ref type="bibr" target="#b23">(He et al., 2010)</ref>.</s><s>The fact that high doses of AT 1 receptor antagonists are required to induce anti-obesity effects <ref type="bibr" target="#b51">(Müller-Fielitz et al., 2011;</ref><ref type="bibr" target="#b47">Müller-Fielitz et al., 2014)</ref> may indicate that the underlying mechanism involves the CNS because the lipophilicity of these antagonists is low, which limits blood-brain barrier (BBB) penetration <ref type="bibr" target="#b38">(Michel et al., 2013)</ref>.</s><s>Thus, high doses of AT 1 receptor antagonists may be necessary in particular to affect energy intake and expenditure, while normal doses may help to control glucose and regulate blood pressure <ref type="bibr" target="#b51">(Müller-Fielitz et al., 2011;</ref><ref type="bibr" target="#b47">Müller-Fielitz et al., 2014)</ref>.</s><s>The hypothesis of a brain-related mechanism is supported by the observations that (i) orally administered AT 1 receptor antagonists were able to antagonize pressure responses to centrally administered angiotensin II (AngII), giving evidence for BBB penetration of the antagonists <ref type="bibr" target="#b18">(Gohlke et al., 2001;</ref><ref type="bibr" target="#b17">Gohlke et al., 2002)</ref>; (ii) hypothalamic orexigenic peptides were suppressed during treatment with AT 1 receptor antagonists <ref type="bibr" target="#b51">(Müller-Fielitz et al., 2011;</ref><ref type="bibr" target="#b54">Noma et al., 2011;</ref><ref type="bibr" target="#b49">Müller-Fielitz et al., 2015)</ref>; (iii) the stress-induced stimulation of the hypothalamus-pituitary-adrenal (HP A) axis was attenuated in rats by AT 1 receptor antagonists, which was further associated with reduced intake of cafeteria diet (CD) <ref type="bibr" target="#b40">(Miesel et al., 2012)</ref>; and (iv) the leptin sensitivity was restored during treatment with AT 1 receptor antagonists <ref type="bibr" target="#b47">(Müller-Fielitz et al., 2014;</ref><ref type="bibr" target="#b49">Müller-Fielitz et al., 2015)</ref>.</s></p><p><s>Because both peripheral and centrally-driven mechanisms may have anti-obesity effects during treatment with AT 1 receptor antagonists, we aimed in this study to gather more evidence showing that an attenuated AT 1 receptordependent signalling mediates weight reduction in a CNSdependent manner.</s><s>Because of the lack of brain-specific double AT 1A /AT 1B receptor KO mice, we used transgenic rats with low brain angiotensinogen (TGR(ASrAOGEN)) as an experimental model of brain-specific, reduced Ang II signalling <ref type="bibr" target="#b62">(Schinke et al., 1999)</ref>.</s><s>Because the TGR(AsrAOGEN) rats were generated on the Sprague Dawley (SD) rat genetic background and all breeding since has been performed on this background, we considered SD rats to be the correct controls.</s><s>In TGR(ASrAOGEN) rats, the concentration of angiotensinogen protein was markedly reduced, compared with controls in medulla, pons, thalamus, cerebellum and particularly in the hypothalamus, an area that is well known to be involved in energy homeostasis, while plasma concentrations of angiotensinogen and plasma renin activity were similar.</s><s>In terms of body weight, transgenic mice with a global angiotensinogen deficiency gained less weight, independently of feeding with normal chow or a high-fat diet <ref type="bibr" target="#b36">(Massiera et al., 2001b)</ref>.</s><s>Body weights in the TGR(ASrAOGEN) strain werer lower than in wild-type (WT) controls <ref type="bibr" target="#b30">(Kasper et al., 2005;</ref><ref type="bibr" target="#b44">Müller et al., 2010)</ref>.</s><s>As a limitation of the TGR(ASrAOGEN) strain, the marked down-regulation of angiotensinogen in the brain may indeed mimic AT 1 receptor blockade but this deficiency also reduced formation of Ang(1-7), which was recently demonstrated to be involved in regulating body weight <ref type="bibr" target="#b63">(Schuchard et al., 2015)</ref>.</s></p><p><s>We designed our study by particularly addressing the following hypotheses: that the development of diet-induced obesity could be prevented in TGR(ASrAOGEN) rats and that the decreased weight gain following treatment with AT 1 receptor antagonists would be at least partly diminished in TGR(ASrAOGEN) rats.</s><s>To investigate this, CD-fed TGR (ASrAOGEN) rats were treated with telmisartan for 3 months.</s><s>Some of these results have already been presented at the Annual Meetings of the German Society of Experimental and Clinical Pharmacology and Toxicology 2014 and 2015 <ref type="bibr" target="#b57">(Piehl et al., 2014;</ref><ref type="bibr" target="#b74">Winkler et al., 2015)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tables of Links</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animals</head><p><s>All animal care and experimental procedures were in accordance with the NIH guidelines for the care and use of laboratory animals and were approved by the animal ethics committee of the local regulatory authority (Ministerium für Energiewende, Landwirtschaft, Umwelt und ländliche Räume des Bundeslandes Schleswig-Holstein).</s><s>The results of all studies involving animals are reported in accordance with the ARRIVE guidelines <ref type="bibr" target="#b31">(Kilkenny et al., 2010;</ref><ref type="bibr" target="#b37">McGrath and Lilley, 2015)</ref>.</s><s>A total of 120 animals were used in the experiments described here.</s><s>Male TGR(ASrAOGEN)L680 rats (designated in the following as TGR(ASrAOGEN), Max Delbrück Center for Molecular Medicine, Berlin, Germany) and SD rats (Saint-Berthevin, Cedex, France) were used in the experiments.</s><s>The animals were kept at room temperature with a 12 h/12 h dark (14:00-2:00 h)/light (2:00-14:00 h) cycle.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Feeding and treatment protocols</head><p><s>Protocol 1. Group sizes of n = 13 were estimated a priori by a power analysis and considering a difference of approximately 100 g between chow and CD feeding as the primary effect size, an α-value of 0.008 and a power size of 0.815.</s><s>At the age of 4 weeks, rats arrived in the laboratory and were kept in pairs.</s><s>After a 2 week habituation period, a total of 26 TGR (ASrAOGEN) and 26 SD rats were randomized to one of the two groups per strain.</s><s>One group of TGR(ASrAOGEN) and SD rats, respectively, was fed solely with standard chow (Maintenance 1320; Altromin, Lage, Germany).</s><s>This feeding regimen is designated as 'control' throughout this text.</s><s>A second group of TGR(ASrAOGEN) and SD rats had free access throughout the entire duration of the study to standard chow plus one of six various commercial chocolate/cookie bars, these being switched daily in a regular manner.</s><s>This feeding regimen is designated as 'CD' throughout this text <ref type="bibr" target="#b39">(Miesel et al., 2010)</ref>.</s><s>Blood samples were taken before and at weeks 4, 8 and 12 (all nonfasting) and at week 9 and 11 (fasting for 18 h) from a tail nick.</s><s>Animals were phenotyped regarding fat mass (week 8) by using MRI techniques <ref type="bibr" target="#b39">(Miesel et al., 2010)</ref>, energy expenditure (week 11) by using the PhenoMaster/InfraMot System ™ (TSE, Bad Homburg, Germany) <ref type="bibr" target="#b47">(Müller-Fielitz et al., 2014;</ref><ref type="bibr" target="#b63">Schuchard et al., 2015)</ref> and insulin sensitivity (oral glucose tolerance test (OGTT)], week 12 <ref type="bibr" target="#b39">(Miesel et al., 2010)</ref>.</s><s>In week 8, abdominal girth and body length (not including tail length) were determined in a blinded manner to calculate the body mass index (BMI).</s><s>After 12 weeks, rats were killed, and organs were removed.</s><s>After preparing the femur, its length was measured using a vernier calliper.</s><s>During the study and functional phenotyping, some rats unexpectedly died, and some animals had to be excluded from further study.</s><s>Thus, this part of the study ultimately had the following group sizes: triglycerides (TG) chow n = 12, SD chow n = 10; TG CD n = 12, SD CD n = 13.</s><s>Protocol 2. Based on an a priori power analysis, the group size was estimated to be n = 17 (60 g difference in body weight as the primary effect size, α-value: 0.008, power 0.78).</s><s>For reasons of breeding and availability of animals, a total of 38 TGR(ASrAOGEN) and 30 SD rats arrived at the age of 4 weeks rats in the laboratory and were kept in pairs.</s><s>After a 2 week habituation period, TGR(ASrAOGEN) and SD rats were randomized to one of the two groups per strain.</s><s>To address the question of whether the weight loss induced by AT 1 receptor antagonists was mediated via a CNS pathway, one group of SD and TGR(ASrAOGEN) rats was treated with telmisartan (Boehringer Ingelheim Pharmaceuticals, Inc., Ingelheim, Germany) for the same time as they were fed the CD diet (8 mg•kg À1 , once per day by gavage, for 14 weeks), whereas a second group of CD-fed SD and TGR(ASrAOGEN) rats received vehicle instead of telmisartan.</s><s>Blood samples (non-fasting, before, after weeks 4, 8 and 12 and fasting for 18 h at weeks 9 and 11) were taken.</s><s>All animals were monitored for body weight, energy intake and energy expenditure (week 11), leptin sensitivity (week 12) <ref type="bibr" target="#b49">(Müller-Fielitz et al., 2015)</ref>, glycemic control (OGTT at week 13) and fat mass distribution (week 13).</s><s>At week 14, rats were killed, and organs were removed.</s><s>Adipocytes were isolated for the glucose uptake assay according to <ref type="bibr" target="#b61">(Santos et al., 2008</ref><ref type="bibr" target="#b59">(Santos et al., , 2010))</ref>.</s><s>During the study and functional phenotyping, some rats unexpectedly died, and some animals had to be excluded from further study.</s><s>Thus, this part of the study ultimately had the following group sizes: TG VEH n = 17, SD VEH n = 15; TG TEL n = 19, SD TEL n = 15.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biochemical analysis</head><p><s>To determine AngII, blood (2 mL) was collected into an inhibitor solution containing 15.4 mM EDTA and 20 μM bestatin (final concentration).</s><s>Plasma concentrations of insulin, adiponectin and glucagon (all from Millipore, St. Charles, MO, USA) or AngII (IBL, Hamburg, Germany) were determined by radioimmunoassay using commercial kits.</s><s>Plasma concentrations of leptin were measured by commercial radioimmunoassay (Millipore) as well as ELISA (R&amp;D Systems, Inc., Minneapolis, MN, USA).</s><s>TG and high-density lipoproteins (HDL) were quantified in the plasma of fasting animals using a Roche/Hitachi Modular P Chemistry Analyzer (Mannheim, Germany) <ref type="bibr" target="#b47">(Müller-Fielitz et al., 2014</ref><ref type="bibr">, 2015;</ref><ref type="bibr" target="#b63">Schuchard et al., 2015)</ref>.</s><s>Blood glucose was determined using glucose sensors (Ascensia® ELITE; Bayer, Leverkusen, Germany).</s><s>RNA was isolated from the hypothalamus, cDNA was synthesized and mRNA levels were quantified by using real-time quantitative polymerase chain reaction.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histology of liver and fat tissue</head><p><s>Formaldehyde-fixed, paraffin-embedded sections of liver and epididymal fat pads were stained with haematoxylin and eosin (H&amp;E) according to the standard protocol of GILL.</s><s>A pathologist unaware of the animal grouping evaluated the slides and scored each liver tissue specimen for hepatocytes with steatosis <ref type="bibr" target="#b63">(Schuchard et al., 2015)</ref> and each fat sample for macrophage infiltration.</s><s>Size of adipocytes was evaluated by counting 10 cells per animal in a blinded manner using LABSENS® version 1.1 2010 supported by Olympus (Hamburg, Germany)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data and statistical analysis</head><p><s>These studies comply with the recommendations on experimental design and analysis in pharmacology <ref type="bibr" target="#b7">(Curtis et al., 2015)</ref>.</s><s>Means and upper and lower quartiles are depicted as boxplots.</s><s>Whiskers indicate variability between the 10th and 90th percentiles.</s><s>In line graphs and tables, data are expressed as means ± SEM.</s></p><p><s>As described previously, rats were fed either with chow or with chow plus chocolate/cookie bars.</s><s>Because of the different calorie values of chow (11.7 kJ•g À1 ) and chocolate/ cookie bars (20.8 kJ•g À1 ), we individually calculated the energy intake (in kJ) of each rat to correctly assess food intake on the basis of the consumed amounts of chow and chocolate/cookie bars.</s></p><p><s>Food efficiency ratio (FER) was calculated according to the equation 'FER = body weight gain • total energy À1 '.</s><s>Homeostatic model assessment (HOMA) index was calculated considering plasma levels of fasting animals according to the formula 'insulin (μU•mL À1 ) • glucose (mg•dL À1 )•405 À1 '.</s><s>The amount of fat was semi-automatically quantified in retroperitoneal fat pads and in subcutaneous fat on the basis of the transverse T1-weighted turbo spin-echo images by using the freeware MRIcro version 1.4 build 1 (http://downloads.</s><s>fyxm.net/MRIcro-117936.html)</s><s>and the V itom for Windows software (Essen, Deutschland).</s><s>Only intensity signals of 70 grey scales were considered to ensure that fat was being analysed <ref type="bibr">(V ogt et al., 2007)</ref>.</s><s>In order to quantify the total effect over the observation period in response to OGTT for changes in plasma concentrations of glucose, the areas under the curve were calculated for each individual animal on the basis of their delta values.</s><s>C max values were also calculated considering delta values.</s><s>All data were checked for outliers using the GRAPHP AD® outlier calculator and tested for Gaussian distribution.</s><s>A two-way analysis of variance (ANOV A) was performed to examine the effects of two variables.</s><s>Pvalues given in the figures originated from two-way ANOV A by testing strain differences.</s><s>P-values given in legends originated from two-way ANOVA by testing diet differences (protocol 1; P diet 2-way ANOV A ) or drug differences (protocol 2; P drug 2-way ANOVA ).</s><s>Bonferroni's post hoc test for multiple comparisons test was only performed if F achieved P &lt; 0.05 and there was no significant variance inhomogeneity.</s><s>Differences were considered to be statistically significant at P &lt; 0.05.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Results for TGR(ASrAOGEN) before any feeding or treating regimen At the age of 6 weeks, body weight of TGR(ASrAOGEN) was lower than in wild-type controls in both protocols (Tables <ref type="table" target="#tab_1">1, 2;  Figures 1A and 4A</ref>).</s><s>Plasma leptin levels did not differ between the two strains (Figure <ref type="figure" target="#fig_1">1B</ref>), while adiponectin was markedly higher in TGR(ASrAOGEN) than in SD rats (Figure <ref type="figure" target="#fig_1">S1</ref>) Fasting glucose of TGR <ref type="bibr">(ASrAOGEN)</ref> and SD rats at the age of 6 weeks was similar (3.35 ± 0.17 vs. 3.33 ± 0.18 mmol•L À1 ).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Influence of CD feeding on TGR(ASrAOGEN) with a brain-specific angiotensinogen deficiency</head><p><s>Weight regulation and energy balance.</s><s>Gain in body weight differed in a strain-dependent manner.</s><s>Because femurs, body lengths and kidneys were smaller in TGR(ASrAOGEN) than in SD rats (Table <ref type="table">1</ref>), growth of TGR(ASrAOGEN) rats is thought to be less than that of SD rats.</s><s>However, SD rats clearly became obese under CD feeding because BMI, girth and fat mass also increased (Table <ref type="table">1</ref>, Figures <ref type="figure" target="#fig_2">1A, S2A</ref>).</s><s>Hence, plasma levels of leptin, TG and also adiponectin increased, while HDL decreased (Table <ref type="table">1</ref>, Figures <ref type="figure" target="#fig_1">1B-D,  S1C</ref>).</s><s>In contrast, TGR(ASrAOGEN) did not become obese despite CD feeding (Table <ref type="table">1</ref>, Figures <ref type="figure" target="#fig_2">1A, S2A</ref>).</s><s>Plasma levels of lipids and leptin remained unaltered (Figure <ref type="figure" target="#fig_1">1B-D</ref>), while adiponectin also increased (Figure <ref type="figure" target="#fig_1">S1C</ref>).</s><s>Plasma AngII levels of chow-fed SD rats were 9.1 ± 0.8 pmol•L À1 and were not influenced by CD feeding or by strain (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 1</head><p><s>Growth of SD and TGR(ASrAOGEN) rats after long-term feeding with high-calorie cafeteria diet SD CON SD CD TG CON TG CD Two-way ANOVA P-values Weights of livers were higher in SD than in TGR(ASrAOGEN) rats.</s><s>CD feeding further increased liver weights selectively in SD rats while left ventricular weight as enhanced in both strains (Table <ref type="table">1</ref>).</s><s>The level of steatosis was also higher in these rats (Figure <ref type="figure" target="#fig_3">S3A</ref>).</s><s>The energy intake was higher when rats were fed with CD, which was more distinct in SD than in the TGR(ASrAOGEN) strain (ANOV A P-values indicating strain differences for diet &lt;0.0001 and time &lt;0.0001) (Figures 1E, 2E, S4A).</s><s>However, CD feeding only increased energy intake in both strains during the dark period (Figure <ref type="figure" target="#fig_2">2E</ref>).</s><s>In TGR(ASrAOGEN) rats, the food efficiency ratio was lower than in SD rats, and furthermore, this  parameter was reduced when TGR(ASrAOGEN) rats were fed with CD (Figure <ref type="figure" target="#fig_1">1I</ref>).</s></p><formula xml:id="formula_0">(n = 10) (n = 13) (n = 12) (n =</formula><p><s>In CD-fed, but not chow-fed SD rats, final plasma leptin concentrations positively correlated with food intake, which indicates leptin resistance (Figure <ref type="figure" target="#fig_5">S5A</ref>).</s><s>The hypothalamic mRNA levels of the anorexigenic peptide pro-opiomelanocortin (POMC) were increased only in the TGR (ASrAOGEN) rats (Figure <ref type="figure" target="#fig_1">1G</ref>).</s><s>Water intake was lower in TGR(ASrAOGEN) rats only but was reduced by CD feeding in both strains (Figure <ref type="figure" target="#fig_1">1H</ref>).</s><s>mRNA levels of leptin receptor in hypothalamus of chow-fed SD rats were 1.0 ± 0.7 × 10 4 copies•ng RNA À1 and not influenced by strain or diet (data not shown).</s><s>Hypothalamic mRNA levels of glial fibrillary acidic protein (GF AP) differed strain dependently (SD CON : 18.7 ± 1.6 × 10 5 , SD CD : 19.7 ± 1.1 × 10 5 , TG CON : 14.3 ± 0.6 × 10 5 , TG CD : 15.4 ± 0.7 × 10 5 copies•ng RNA À1 , P = 0.0002).</s><s>mRNA levels of AT 1B receptor were reduced in the hypothalami of TGR(ASrAOGEN) rats, but those of AT 1A and AT 2 receptors did not differ between strains (Figure <ref type="figure" target="#fig_6">S6A</ref>).</s><s>The energy expenditure (EE) varied between the strains and increased particularly in CD-fed TGR(ASrAOGEN) rats during the dark period (Figures 2A, S4A; P diet 2-way ANOVA for EE dark is 0.0013).</s><s>Moreover, the respiratory exchange rate (RER) was strain-dependently lower in TGR(ASrAOGEN) rats and selectively reduced during CD feeding within the light period (Figures 2B, S4A; P diet 2-way ANOVA for RR light is &lt;0.0001).</s><s>There was less locomotion in the TGR(ASrAOGEN) strain, but it increased in particular during the dark period when they were fed with CD (Figures 2C, S4A; P diet 2-way ANOVA for locomotion dark is 0.006).</s></p><p><s>Glucose control.</s><s>Because of CD feeding, baseline levels of both glucose and insulin and the HOMA index were selectively increased in SD, but not in TGR(ASrAOGEN) rats (Figure <ref type="figure" target="#fig_3">3A-D</ref>).</s></p><p><s>The glucose response in OGTT was higher in TGR(ASrAOGEN) rats (Figure <ref type="figure" target="#fig_3">3E-G</ref>).</s><s>In contrast, the insulin response in OGTT was clearly increased in CD-fed SD rats (Figure <ref type="figure" target="#fig_3">3H-J</ref>), indicating insulin resistance, which was also suggested from the baseline levels.</s></p><p><s>Results of treating CD-fed SD and TGR (ASrAOGEN) rats with telmisartan Weight regulation and energy balance.</s><s>In accordance with the first part of our study, body weights and plasma levels of leptin and triglycerides in the TGR(ASrAOGEN) rats were clearly lower (Table <ref type="table" target="#tab_1">2 and Figure</ref>  <ref type="figure" target="#fig_4">4</ref>).</s><s>Obesity was markedly improved when SD rats were treated with telmisartan in parallel to CD feeding because weight gain, BMI, girth and fat mass were diminished (Table <ref type="table" target="#tab_1">2</ref>, Figures <ref type="figure" target="#fig_4">4A, S2B</ref>).</s><s>Liver weights were strain-dependently lower in TGR(ASrAOGEN) than in SD rats.</s><s>Telmisartan lowered left ventricular weight in both strains, too.</s><s>An overall, strain-independent telmisartan effect on liver weight was found (P = 0.0312, Table <ref type="table" target="#tab_1">2</ref>).</s><s>Steatosis was lower in TGR(ASrAOGEN) rats but remained strain independently unaffected by telmisartan treatment (Figure <ref type="figure" target="#fig_3">S3B</ref>).</s><s>Macrophage infiltration into fat tissue was reduced when CD-fed SD rats were treated with telmisartan, but this was never observed in TGR(ASrAOGEN) rats (Figure <ref type="figure" target="#fig_8">S8</ref>).</s><s>Moreover, leptin and triglycerides decreased, while HDL (Figure <ref type="figure" target="#fig_4">4B-D</ref>) increased.</s><s>In contrast, markedly fewer telmisartan effects on weight gain, girth, fat mass or lipid levels were observed in the TGR (ASrAOGEN) strain.</s><s>(Table 2, Figure <ref type="figure" target="#fig_5">5B-D</ref>).</s><s>An overall effect of telmisartan treatment on adiponectin was detected for both strains (P = 0.0142, Figure <ref type="figure" target="#fig_1">S1D</ref>).</s><s>The number of adipocytes per g fat mass was clearly higher in epidymial fat of TGR (ASrAOGEN) rats and particularly after telmisartan treatment, but the cell area was halved when compared with adipocytes from SD rats.</s><s>Thus, size and amount of adipocytes correlated negatively (Figure <ref type="figure" target="#fig_7">S7</ref>).</s><s>Size of adipocytes tended to be strain independently reduced when animals were treated with telmisartan (P = 0.08) (Figure <ref type="figure" target="#fig_7">S7D,F,G</ref>).</s><s>During the course of telmisartan treatment, energy intake lessened in both SD and TGR(ASrAOGEN) rats (Figure <ref type="figure" target="#fig_4">4E</ref>).</s><s>The FER was again lower in TGR(ASrAOGEN) and reduced by telmisartan only in SD rats (Figure <ref type="figure" target="#fig_4">4E</ref>) Hypothalamic mRNA levels of POMC were found not to be decreased by telmisartan (Figure <ref type="figure" target="#fig_5">5G</ref>).</s><s>Telmisartan did not affect water intake either (Figure <ref type="figure" target="#fig_4">4H</ref>).</s><s>mRNA levels of leptin receptor in hypothalamus were not influenced by strain or telmisartan (data not shown).</s><s>In accordance with the first part of our study, hypothalamic mRNA levels of GF AP were lower in TGR(ASrAOGEN) (P &lt; 0.0001) and, moreover, were reduced in both strains after telmisartan treatment (P = 0.03) (SD VEH : 18.0 ± 1.2 × 10 5 , SD TEL : 15.6 ± 0.9 × 10 5 , TG CON : 12.1 ± 0.6 × 10 5 , TG CD : 10.7 ± 0.7 × 10 5 copies•ng RNA À1 , P = 0.0002).</s><s>Levels of mRNA for AT 1B receptors were reduced in the hypothalami of TGR(ASrAOGEN) rats, while those of AT 1A and AT 2 receptors did not differ (Figure <ref type="figure" target="#fig_6">S6B</ref>).</s><s>GFAP was reduced in TGR(ASrAOGEN) rats, while AT 1A and AT 1B receptors did not differ (Figure <ref type="figure" target="#fig_6">S6B</ref>).</s><s>We also tested whether leptin sensitivity might be altered by telmisartan.</s><s>In response to exogenous leptin applications, body weight decreased in SD rats when treated with telmisartan, which indicates that leptin sensitivity was maintained (Figure <ref type="figure" target="#fig_5">5</ref>).</s><s>Food intake only tended to be decreased in these rats.</s><s>In TGR(ASrAOGEN) rats, telmisartan did not increase responses to leptin (Figure <ref type="figure" target="#fig_5">5</ref>).</s><s>Energy expenditure was also found in this part of the study to be higher in TGR(ASrAOGEN) than in SD rats without being further influenced by telmisartan in either strain (Figure <ref type="figure" target="#fig_6">6A</ref>) although less locomotion was observed in this strain particularly during the light period (Figure <ref type="figure" target="#fig_6">6C</ref>).</s><s>However, treatment with telmisartan decreased RER in SD rats during the dark period and in TGR(ASrAOGEN) rats during the light phase (Figure <ref type="figure" target="#fig_6">6B</ref>).</s></p><p><s>Glucose control.</s><s>Strain differences with lower insulin levels in the TGR(ASrAOGEN) strain and attenuated glucose and insulin responses in OGTT were also seen in this part of our study (Figure <ref type="figure" target="#fig_7">7</ref>).</s><s>Telmisartan did not affect fasting glucose in either strain, but insulin was reduced in SD rats (Figure <ref type="figure" target="#fig_7">7B</ref>).</s><s>Telmisartan also lowered the glucose response in OGTT in SD rats, while the insulin response remained constant.</s><s>In TGR (ASrAOGEN) rats, telmisartan clearly diminished the insulin response in OGTT, while the glucose response only tended to be reduced (Figure <ref type="figure" target="#fig_7">7D-I</ref>).</s><s>To further determine glucose control, uptake studies were performed on isolated adipocytes.</s><s>Glucose uptake was clearly higher in adipocytes (originating from 1 g fat) of TGR(ASrAOGEN) rats, which was further enhanced in telmisartan-treated TGR(ASrAOGEN) rats (Figure <ref type="figure" target="#fig_8">8A</ref>).</s><s>Considering the number of adipocytes in epidymial fat and the total epidymial fat mass, the glucose uptake per adipocyte and per total fat mass, respectively, was similar among all groups (Figure <ref type="figure" target="#fig_8">8B-C</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The main finding of our study is that selective inhibition of the brain RAS by genetic means prevents CD-induced obesity, supporting a role of the brain RAS in metabolic regulation.</s><s>In line with the first publication on TGR(ASrAOGEN) rats <ref type="bibr" target="#b62">(Schinke et al., 1999)</ref>, we also observed here that baseline levels of AngII were indeed similar between TGR(ASrAOGEN) and SD rats, but that drinking responses were markedly reduced in the transgenic animals, which confirms the biochemical and functional down-regulation of brain angiotensinogen in the TGR(ASrAOGEN) strain.</s><s>The AngIIdependent dipsogenic action was related to an AT 1B receptor-mediated mechanism <ref type="bibr" target="#b8">(Davisson et al., 2000)</ref>.</s><s>In agreement with others, we also found that hypothalamic expression of AT 1A receptors exceeded that of AT 1B receptors <ref type="bibr" target="#b28">(Jöhren et al., 1995;</ref><ref type="bibr" target="#b8">Davisson et al., 2000)</ref>, but expression was lower in TGR(ASrAOGEN) rats, which did not reflect increased AngII binding as others have shown <ref type="bibr" target="#b41">(Monti et al., 2001)</ref>.</s><s>Thus, we assume that hypothalamic levels of mRNA for AT 1B receptors only reflect expression of these receptors, to a minor degree.</s><s>Although increased water intake in response to intravenous AngII administration was blocked by intracerebroventricular AT 1 receptor blockade <ref type="bibr" target="#b25">(Hohle et al., 1995)</ref>, drinking responses after telmisartan were not reduced, which was also found in another recent study <ref type="bibr" target="#b63">(Schuchard et al., 2015)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effects on body weight</head><p><s>We have found that body length, femur, livers and kidneys are smaller in the TGR(ASrAOGEN) strain, suggesting that growth in general is reduced in transgenic animals, which is in line with the findings of other authors <ref type="bibr" target="#b30">(Kasper et al., 2005;</ref><ref type="bibr" target="#b19">Groban et al., 2012)</ref>.</s><s>However, the strain-dependent decrease in BMI, girth and visceral fat mass also indicates that not only is animal growth impaired but also that development of obesity can be prevented particularly in TGR(ASrAOGEN) rats (especially when fed with CD), which was associated with maintenance of normal lipid profiles and glucose control.</s><s>Less weight gain was also found in angiotensinogen-deficient mice [showing no detectable plasma levels of angiotensinogen and angiotensin I (AngI) <ref type="bibr" target="#b69">(Tanimoto et al., 1994)</ref>] compared with WT controls although their intake of a high-fat diet was not lower <ref type="bibr">(Massiera et al., 2001a,b)</ref>.</s><s>In contrast, specific overexpression of angiotensinogen in adipose tissue induced obesity <ref type="bibr" target="#b35">(Massiera et al., 2001a)</ref>.</s><s>Considering that angiotensinogen is the unique substrate of renin and the precursor of AngII after the initial product, AngI, is metabilised by ACE, it seems confusing that body weight increased when angiotensinogen was overexpressed and reduced when it is deficient because, on the one hand, AngII induced weight loss after peripheral <ref type="bibr" target="#b4">(Cabassi et al., 2005;</ref><ref type="bibr" target="#b66">Song et al., 2005;</ref><ref type="bibr" target="#b77">Zhang et al., 2009;</ref><ref type="bibr" target="#b50">Müller-Fielitz et al., 2012b;</ref><ref type="bibr" target="#b52">Müller-Fielitz and Raasch, 2013;</ref><ref type="bibr" target="#b68">Tabony et al., 2014)</ref> and brain-specific administration of <ref type="bibr">AngII (de Kloet et al., 2011)</ref> and, on the other hand, plasma levels of angiotensinogen or AngII positively correlated with body weight in obesity <ref type="bibr" target="#b13">(Engeli et al., 2005;</ref><ref type="bibr" target="#b22">Harte et al., 2005)</ref>.</s><s>Addressing this discrepancy, properly balanced angiotensinogen levels in adipocytes must be maintained for normal adipose tissue growth and weight gain.</s><s>Indeed, overexpression of angiotensinogen in adipose tissue induced obesity, whereas restricted angiotensinogen expression in adipose tissue was more likely to reduce body weight <ref type="bibr" target="#b35">(Massiera et al., 2001a)</ref>.</s></p><p><s>Regarding the underlying mechanisms of preventing obesity, we have shown in this study that energy intake was lower throughout the entire observation period of 12 weeks in the TGR(ASrAOGEN) strain.</s><s>In contrast, others had observed that body weight-related food intake was increased in TGR (AsrAOGEN) rats despite weight loss <ref type="bibr" target="#b30">(Kasper et al., 2005)</ref>.</s><s>This inconsistency was thought to be not simply due to a suppression of appetite and was interpreted as the result of a centrally mediated long-term effect of AngII on overall body metabolism' <ref type="bibr" target="#b30">(Kasper et al., 2005)</ref>.</s><s>Moreover, we found that FER is lower in transgenic rats and particularly after CD feeding, thus suggesting that food is less sufficiently converted to body weight but more prone to be utilized as energy.</s><s>Indeed, energy expenditure was higher in the TGR(ASrAOGEN) strain particularly when fed with CD.</s><s>Increased locomotor activity, serving as a parameter for energy expenditure, was also detected in angiotensinogen-deficient mice to explain their reduced body weight although the chow intake was similar to wild-type controls <ref type="bibr" target="#b36">(Massiera et al., 2001b)</ref>.</s><s>RER was also lower in TGR(ASrOGEN) than in SD rats, thus indicating higher fat burning.</s><s>This finding also corresponds to our observation that the fat mass is reduced in these rats.</s></p><p><s>Increased action of leptin in the arcuate nucleus (ARC) inhibits the neuropeptide Y /agouti-related protein anabolic pathway and stimulates the proopiomelanocortin/cocaineand amphetamine-regulated transcript (POMC/CART) catabolic pathway.</s><s>Downstream to the ARC, the paraventricular nucleus produces anorexigenic peptides such as corticotrophin-releasing hormone, and the lateral hypothalamus and perifornical area secrete the orexigenic substances orexin-A and melanin-concentrating hormone.</s><s>Here, we observed higher hypothalamic mRNA levels of POMC in TRG(ASrAOGEN) than in SD rats, which is in line with the lower energy intake in this strain.</s><s>Up to now, we only have little evidence for a direct mechanism of how low brain angiotensinogen levels may increase POMC.</s><s>However, we did observe that leptin sensitivity was better in transgenic than in control rats, which may be influenced by the lower triglyceride levels of TGR(ASrAOGEN)rats.</s><s>On the one hand, triglycerides are an important cause of leptin resistance as mediated by impaired transport across the BBB, and on the other, decreasing triglycerides may potentiate the anorectic effect of leptin by enhancing leptin transport across the BBB <ref type="bibr" target="#b1">(Banks et al., 2004)</ref>.</s><s>In vitro experiments on microvessel endothelial cells supporting the notion that AngII directly modulates BBB endothelial cell function by altering both transcellular and paracellular permeability <ref type="bibr" target="#b14">(Fleegal-DeMotta et al., 2009)</ref>.</s><s>Decreases in hypothalamic GF AP may also contribute to the weight loss of TGR(ASrAOGEN) rats, an effect which was also observed in angiotensinogen-deficient mice <ref type="bibr" target="#b29">(Kakinuma et al., 1998)</ref> because obesity was related to enhanced GF AP immunoreactivity or GF AP protein as an indicator for astrogliosis in the CNS <ref type="bibr" target="#b26">(Hsuchou et al., 2009;</ref><ref type="bibr" target="#b3">Buckman et al., 2013;</ref><ref type="bibr" target="#b70">Tomassoni et al., 2013)</ref>.</s></p><p><s>AT 2 receptor-deficient mice showed (i) increased body weight <ref type="bibr" target="#b20">(Gross et al., 2000)</ref> and (ii) lower resting body temperature and locomotor activity <ref type="bibr" target="#b24">(Hein et al., 1995;</ref><ref type="bibr" target="#b27">Ichiki et al., 1995)</ref>.</s><s>Considering these findings, it is permissible to speculate as to whether the imbalance between energy intake and energy expenditure boosting obesity in SD rats when AngII is present is related to AT 2 receptors.</s><s>We did demonstrate the presence of AT 2 receptor mRNA in the hypothalamus, but the levels were not regulated by strain, diet or telmisartan (Figure <ref type="figure" target="#fig_6">S6</ref>).</s><s>Loss of AT 2 receptor expression was found to be sufficient to rescue obesity induced by high-fat feeding <ref type="bibr" target="#b75">(Yvan-Charvet et al., 2005)</ref> or adipose tissue angiotensinogen overexpression <ref type="bibr" target="#b76">(Yvan-Charvet et al., 2009)</ref>, which does strengthen the necessary role of AT 2 receptors for the onset of obesity, but can only support our hypothesis that a CNSmediated mechanism is involved in regulating body weight in diet-induced rat obesity to a minor degree.</s><s>Nevertheless, specifically activating AT 2 receptors with the AT 2 receptor agonist C21, attenuated rebound weight gain after food deprivation and modulated dopamine signalling, while deletion of AT 2 receptors enhanced rebound weight via excessive food intake by increasing dopamine levels in the striatum <ref type="bibr" target="#b53">(Nakaoka et al., 2015)</ref>.</s><s>These findings more strongly support the idea that a brain-related and AT 2 receptor-dependent mechanism may contribute to diet-induced obesity.</s></p><p><s>By treating TGR(ASrAOGEN) rats with telmisartan, we then aimed to answer the question of whether the prevention of weight gain by AT 1 receptor antagonists is likely to be related to a mechanism involving the CNS.</s><s>As shown here, treating SD rats with telmisartan hampered development of obesity and decreased energy intake.</s><s>These effects were also observed in TGR(ASrAOGN) rats.</s><s>Hence, mechanisms involving AT 2 receptors, as discussed previously, or the Ang(1-7)/ Mas receptor pathway, as demonstrated recently <ref type="bibr" target="#b63">(Schuchard et al., 2015)</ref> do not appear to be likely in transgenic rats because AngII cannot be up-regulated and redirected to AT 2 receptors or Ang(1-7) up-regulated, which then acts via Mas, because of the angiotensinogen deficiency in these rats.</s><s>Nonetheless, we were able to demonstrate a robust upregulation of POMC mRNA in TGR(ASrAOGEN) rats in parallel to the decreased food intake.</s><s>However, findings on POMC do seem to be rather counterintuitive because telmisartan had no effect on hypothalamic mRNA levels in SD or TGR (ASrAOGEN) rats.</s><s>In our recent paper, we did not find POMC to be up-regulated after telmisartan <ref type="bibr" target="#b63">(Schuchard et al., 2015)</ref>, which in fact confirms the finding of the present study but unfortunately does not provide a satisfactory answer as to why (an-)orexigenic peptides were not regulated by telmisartan despite alterations in food intake.</s><s>Treating SD rats with telmisartan additionally normalized plasma levels of leptin, TG and HDL, restored leptin sensitivity and decreased energy intake and RER during the dark period, all of which is in agreement with our previous findings <ref type="bibr" target="#b40">(Miesel et al., 2012;</ref><ref type="bibr" target="#b48">Müller-Fielitz et al., 2012a;</ref><ref type="bibr" target="#b47">Müller-Fielitz et al., 2014;</ref><ref type="bibr" target="#b49">Müller-Fielitz et al., 2015)</ref>.</s><s>In contrast, TGR(ASrAOGEN) rats were influenced less by telmisartan, which strengthens the hypothesis of a brain-dependent pathway in weight regulation.</s><s>A small but significant effect of telmisartan on weight gain even in TGR(ASrAOGEN) rats suggests that peripheral pathways seem to be involved in addition to the central mechanism.</s><s>In this regard, weight reduction may be related to reduced growth of adipocytes <ref type="bibr" target="#b78">(Zorad et al., 2006;</ref><ref type="bibr" target="#b48">Müller-Fielitz et al., 2012a)</ref> because effects of telmisartan treatment on adipocyte size were seen in this study when data were analysed with a a one-tailed statistical test (P = 0.043).</s><s>Obesity is widely accepted to be associated with chronic lowgrade inflammation in peripheral organs, accounting for comorbidities such as insulin resistance and cardiovascular diseases.</s><s>Hence, anti-inflammatory effects of AT 1 receptor antagonists may contribute to weight loss after treatment with these agents <ref type="bibr" target="#b5">(Cole et al., 2010;</ref><ref type="bibr" target="#b21">Guo et al., 2011)</ref>.</s><s>Here, we found evidence that telmisartan reduced macrophage infiltration in fat tissue in SD rats, which, however, was not observed in the TGR(ASrAOGEN) strain.</s><s>Obesity additionally   promotes inflammation in the CNS because proinflammatory cytokines <ref type="bibr" target="#b11">(De Souza et al., 2005)</ref> and GF AP immunoreactivity or GF AP protein <ref type="bibr" target="#b26">(Hsuchou et al., 2009;</ref><ref type="bibr" target="#b3">Buckman et al., 2013;</ref><ref type="bibr" target="#b70">Tomassoni et al., 2013)</ref> increased in brain.</s><s>Hypothalamic mRNA levels of GF AP were reduced by telmisartan, which is in line with findings for losartan.</s><s>Losartan normalized GF AP-positive hippocampal areas, which were increased compared with wild-type mice in an Alzheimer's disease transgenic mice model <ref type="bibr" target="#b55">(Ongali et al., 2014)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effects on glucose control</head><p><s>Because obesity is hallmark characteristic feature of the metabolic syndrome and predisposes patients to developing type 2 diabetes mellitus (T2DM) <ref type="bibr" target="#b65">(Sell et al., 2012)</ref>, we investigated as a secondary parameter whether insulin resistance can be hampered in the TGR(ASrAOGEN) strain, in spite of feeding rats with CD and whether telmisartan treatment would have an additional effect on glucose control in this model.</s><s>The adipose tissue is an important endocrine organ: here, leptin is released that inhibits insulin secretion from pancreatic beta cells <ref type="bibr" target="#b12">(Emilsson et al., 1997)</ref>, and adiponectin has the opposite effect <ref type="bibr" target="#b16">(Ghoshal and Bhattacharyya, 2015)</ref>.</s><s>We observed in our study that plasma adiponectin was higher in TGR (ASrAOGEN) rats before the feeding period and increased during CD feeding in both strains, whereas baseline leptin was similar between TGR(ASrAOGEN) and SD rats, and selectively increased when SD rats were fed with CD.</s><s>However, baseline insulin and insulin response in OGTT were similar in chowfed TGR(ASrAOGEN) and SD rats, which is in line with the findings of others <ref type="bibr" target="#b36">(Massiera et al., 2001b;</ref><ref type="bibr" target="#b30">Kasper et al., 2005)</ref> and indicates that insulin is not necessarily regulated under normative conditions in the TGR(ASrAOGEN) strain even when adiponectin is increased.</s><s>However, when animals were fed with CD, SD rats became obese and insulin resistant and had higher adiponectin and leptin levels; none of which was seen in TGR(ASrAOGEN) rats except for the increase in adiponectin.</s><s>This allowed us to conclude that the better glucose control, as seen in TGR(ASrAOGEN) rats, may not simply be related to alterations in the leptin-dependent and/or adiponectin-dependent insulin release.</s><s>We further asked whether glucose transport in adipocytes might be different between TGR(ASrAOGEN) and SD rats because glucose uptake in adipose tissue is suggested to be down-regulated by leptin <ref type="bibr" target="#b43">(Muller et al., 1997)</ref> and enhanced by adiponectin <ref type="bibr" target="#b73">(Vu et al., 2007)</ref>.</s><s>When related to similar amounts of fat tissue, it seems likely that glucose uptake into adipocytes is higher in TGR(ASrAOGEN) than in SD rats, which may support the in vivo findings on adiponectin <ref type="bibr" target="#b73">(Vu et al., 2007)</ref>.</s><s>However, due to the reduced cell size and increased number of adipocytes, glucose uptake per single adipocyte did not differ between the stains, which gives rise to doubt about whether this mechanism really does help to improve the control of glucose levels in TGR(ASrAOGEN) rats.</s><s>The expansion of the fat mass in obesity goes hand in hand with infiltration of proinflammatory immune cells into adipose tissue, causing chronic, low-grade inflammation, and with nonalcoholic steatohepatitis.</s><s>These effects were demonstrated to contribute to development of T2DM <ref type="bibr" target="#b65">(Sell et al., 2012;</ref><ref type="bibr" target="#b2">Birkenfeld and Shulman, 2014)</ref>.</s><s>The relevance of both pathomechanisms was shown in SD rats because obesity and T2DM after CD feeding coincidently occurred with both macrophage infiltration as a sign of adipose tissue inflammation and with hepatic steatosis, all of which was not observed in TGR(ASrOGEN) rats.</s><s>This strengthens the notion that the improved glucose control of these rat strains may be linked to their feature not to develop inflammation.</s></p><p><s>In agreement with numerous experimental and clinical findings, we also observed here that telmisartan ameliorates glucose utilization, particularly in CD-fed SD.</s><s>This has been broadly discussed to be related to the potency of telmisartan to stimulate PP ARγ <ref type="bibr" target="#b34">(Kintscher et al., 2008)</ref>.</s><s>We only have poor evidence that this PP ARγ-dependent mechanism contributes to improved glucose homeostasis of CD-fed SD rats because adiponectin, which is one of the target genes for PP ARγ, was not up-regulated in these rats, which is in line with findings also showing that improved insulin sensitivity after treatment with AT 1 receptor antagonists occurs independently of PP ARγ regulation <ref type="bibr" target="#b48">(Müller-Fielitz et al., 2012a)</ref>.</s><s>Thus, we assume that the improved glucose utilization after AT 1 receptor blockade is related more to the anti-inflammatory properties of these antagonists, which was demonstrated in this study by lower macrophage infiltration into adipose tissue and which was suggested to further protect islet function <ref type="bibr" target="#b5">(Cole et al., 2010)</ref>.</s><s>Moreover, improved glucose homeostasis after AT 1 receptor blockade may also be attributed to normalized reactivity of the stress-axis because AngII increased stress responses and concurrently worsened glucose homeostasis in obese rats <ref type="bibr" target="#b45">(Müller et al., 2007;</ref><ref type="bibr" target="#b52">Müller-Fielitz and Raasch, 2013)</ref>, whereas telmisartan lowered both corticosterone and glucose levels after stress <ref type="bibr" target="#b58">(Raasch et al., 2006;</ref><ref type="bibr" target="#b40">Miesel et al., 2012)</ref>.</s><s>However, we did not generate any data in the present study supporting this probable mechanism.</s></p><p><s>In summary, we clearly show in this study that rats with a selective brain angiotensinogen deficiency are protected from developing diet-induced obesity and that the reduced weight gain after treatment with AT 1 receptor antagonists can at least partly be attributed to a brain-related mechanism.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Growth and food intake of TGR(ASrAOGEN) and SD rats after control or CD feeding (TG chow n = 12, SD chow n = 10, TG CD n = 12, SD CD n = 13; Protocol 1. (A) Gain in body weight during experiment.</s><s>(B) Plasma leptin are enhanced by CD feeding in SD (P diet 2-way ANOVA &lt; 0.0001), but not in TGR(ASrAOGEN) rats.</s><s>Plasma concentrations at the end of the study of triglycerides (C) (P diet 2-way ANOVA &lt; 0.0001) and HDL (D) (P diet 2-way ANOVA =-0.0001).</s><s>(E) Energy intake after control or CD feeding during the study (P diet 2-way ANOVA for both SD and TG rats is 0.0001).</s><s>(F) Food efficiency ratio (FER; P diet 2-way ANOVA = 0.0012), (G) hypothalamic POMC expression (P diet 2-way ANOVA = 0.024).</s><s>(H) water intake per week (P diet 2-way ANOVA &lt; 0.0001).</s><s>Means ± SEM are shown in line graphs; means and upper and lower quartiles as boxplots.</s><s>Whiskers indicate variability between the 10th and 90th percentile; *P &lt; 0.05 after Bonferroni's post hoc test.</s></p></div></figDesc><graphic coords="5,98.93,342.99,396.17,206.93" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Energy expenditure (A) (P diet 2-way ANOVA for EE dark = 0.0013), respiratory ratio (B) (P diet 2-way ANOVA = 0.025 , P drug 2-way ANOVA &lt; 0.0001), locomotion (C) (P diet 2-way ANOVA for locomotion dark = 0.006) and energy intake (D) (P diet 2-way ANOVA for energy intake dark &lt; 0.0001) considering light and dark periods during indirect calorimetry measurements of TGR(ASrAOGEN) and SD rats after control or CD feeding (TG chow n = 12, SD chow n = 10; TG CD n = 12, SD CD n = 13).</s><s>Animals were housed for 3 days in calorimetry cages, but only the data from the third day are shown.</s><s>Means and upper and lower quartiles are shown as boxplots.</s><s>Whiskers indicate variability between the 10th and 90th percentile.</s><s>*P &lt; 0.05 versus appropriate control-fed rats after Bonferroni's post hoc test.</s></p></div></figDesc><graphic coords="6,98.25,56.98,397.60,195.31" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 CD</head><label>3</label><figDesc><div><p><s>Figure 3 CD feeding impaired glucose utilization in SD, but not in TGR(ASrAOGEN) rats (TG chow n = 12, SD chow n = 10, TG CD n = 12, SD CD n = 13).</s><s>(A) Baseline fasting glucose levels (P diet 2-way ANOVA = 0.0069), (B) baseline fasting insulin levels (P diet 2-way ANOVA = 0.008), (C) HOMA index (P diet 2-way ANOVA -= 0.003), (D) baseline fasting glucagon levels (P diet 2-way ANOVA = 0.003), (E) plasma glucose levels in response to an oral glucose tolerance test (1 g glucose•kg bw À1 ), AUC (F) (P diet 2-way ANOVA = 0.017) and C max (G) values of plasma glucose time curves.</s><s>(H) Plasma insulin levels in OGTT, AUC (I) P diet 2-way ANOVA &lt; 0.0001) and C max (J) (P diet 2-way ANOVA = 0.018) values of plasma glucose time curves.</s><s>Means ± SEM are shown in line graphs; means and upper and lower quartiles as boxplots.</s><s>Whiskers indicate variability between the 10th and 90th percentile.</s><s>*P &lt; 0.05 versus appropriate control-fed rats after Bonferroni's post hoc test.</s><s>AUC, area under control.</s></p></div></figDesc><graphic coords="7,98.76,56.98,396.63,325.19" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 4</head><label>4</label><figDesc><div><p><s>Figure 4Growth and food intake of TGR(ASrAOGEN) and SD rats after CD feeding and treatment with telmisartan (TEL, 8 mg•kgÀ1 •d À1 , 3 months) or vehicle.</s><s>(A) Body weight during experiment (P drug 2-way ANOVA = 0.028 for TG VEH versus TG TEL , P drug 2-way ANOVA = 0.010 for SD VEH versus SD TEL ).</s><s>Plasma concentrations of leptin (B) (P drug 2-way ANOVA = 0.003), triglycerides (C) P drug 2-way ANOVA = 0.0003) and HDL (D) (P drug 2-way ANOVA = 0.026) at the end of the study.</s><s>(E) Energy intake after control or CD feeding during the study (P drug 2-way ANOVA = 0.0034 for TG VEH versus TG TEL , P drug 2-way ANOVA = 0.018 for SD VEH versus SD TEL ).</s><s>(F) Food efficiency ratio (FER; P drug 2-way ANOVA = 0.005).</s><s>(G) Hypothalamic POMC expression, (H) mean water intake per week.</s><s>Means ± SEM are shown in line graphs; means and upper and lower quartiles as boxplots.</s><s>Whiskers indicate variability between the 10th and 90th percentile.</s><s>Group sizes (n) are shown in the figures.</s><s>Data lost in leptin TG and HDL was due to limited blood volume; data lost in POMC was due to technical complications.</s><s>*P &lt; 0.05 versus appropriate vehicle-treated rats after Bonferroni's post hoc test.</s></p></div></figDesc><graphic coords="8,99.16,56.98,395.72,212.71" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 5</head><label>5</label><figDesc><div><p><s>Figure 5 Leptin sensitivity in CD-fed TGR(ASrAOGEN) and SD rats after telmisartan (TEL) treatment was determined by repeated leptin injections over 2 days.</s><s>The grey bars indicate the dark periods.</s><s>(A/B) Gain in body weight after exogenous leptin was selectively attenuated by telmisartan in TGR(ASrAOGEN) compared with SD rats (P drug 2-way ANOVA -= 0.025).</s><s>(C/D) The energy intake after exogenous leptin was lower in TGR(ASrAOGEN) but only tended to be reduced by telmisartan (P drug 2-way ANOVA = 0.066).</s><s>Means ± SEM are shown in line graphs; means and upper and lower quartiles as boxplots.</s><s>Whiskers indicate variability between the 10th and 90th percentile.</s><s>Group sizes: SD VEH n = 12, SD TEL n = 14, TG VEH n = 12, TG TEL n = 16; technical complications in leptin applications led to reduced group sizes.</s><s>*P &lt; 0.05 versus appropriate vehicle-treated rats after Bonferroni's post hoc test.</s></p></div></figDesc><graphic coords="9,42.01,56.98,241.36,214.24" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 6</head><label>6</label><figDesc><div><p><s>Figure 6 Energy expenditure (A), respiratory ratio (B) (P drug 2-way ANOVA for RR light = 0.009 and P drug 2-way ANOVA for RR dark = 0.005), locomotion (C) and energy intake (D) (P drug 2-way ANOVA for energy intake light = 0.035 and P drug 2-way ANOVA for energy intake dark = 0.08) considering light and dark periods during indirect calorimetry measurements.</s><s>Animals were housed for 3 days in calorimetry cages but only the data from the third day are shown.</s><s>Means and upper and lower quartiles are shown as boxplots.</s><s>Whiskers indicate variability between the 10th and 90th percentile.</s><s>Group sizes: SD VEH n = 15, SD TEL n = 15, TG VEH n = 17, TG TEL n = 19; technical complications in calorimetry led to reduced group sizes.</s><s>*P &lt; 0.05 versus appropriate vehicletreated rats after Bonferroni's post hoc test.</s></p></div></figDesc><graphic coords="10,98.48,56.98,397.14,212.09" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 7</head><label>7</label><figDesc><div><p><s>Figure 7 Influence of telmisartan (TEL) on in vivo glucose control in CD-fed SD rats and TGR(ASrAOGEN) rats (=TG).</s><s>(A) Baseline fasting glucose levels, (B) baseline fasting insulin levels (P drug 2-way ANOVA = 0.006), (C) HOMA index (P drug 2-way ANOVA = 0.053), (D) plasma glucose levels in response to an oral glucose tolerance test (1 g glucose•kg bw À1 ), AUC (E) (P drug 2-way ANOVA = 0.040) and C max (F) values of plasma glucose time curves.</s><s>(G) Plasma insulin levels in OGTT, AUC (H) P drug 2-way ANOVA = 0.044) and C max (I) P drug 2-way ANOVA = 0.018) values of plasma glucose time curves.</s><s>Means ± SEM are shown in line graphs; means and upper and lower quartiles as boxplots.</s><s>Whiskers indicate variability between the 10th and 90th percentile.</s><s>Group sizes: SD VEH n = 13, SD TEL n = 14, TG VEH n = 17, TG TEL n = 18; reduced group sizes were due to death of animals prior to OGTT or due to technical complications in glucose applications.*P</s><s>&lt; 0.05 versus appropriate vehicle-treated rats after Bonferroni's post hoc test.</s></p></div></figDesc><graphic coords="11,140.88,56.98,312.41,316.06" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>Figure 8</head><label>8</label><figDesc><div><p><s>Figure 8Influence of telmisartan (TEL) on ex vivo glucose control in CD-fed SD rats and TGR(ASrAOGEN) rats (=TG).</s><s>Glucose uptake in epidymial fat related to 1 g tissue (A) Pdrug 2-way ANOVA = 0.010), adipocyte (B) or total epidymial fat mass (C).</s><s>Means and upper and lower quartiles are shown as boxplots.</s><s>Whiskers indicate variability between the 10th and 90th percentile.</s><s>Group sizes: SD VEH n = 14, SD TEL n = 12, TG VEH n = 11, TG TEL n = 13; because this ex vivo assay was not yet established at the beginning of the study, we were not able to include all animals.</s><s>*P &lt; 0.05 versus appropriate vehicle-treated rats after Bonferroni's post hoc test.</s></p></div></figDesc><graphic coords="11,126.65,540.06,340.76,108.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Growth of CD-fed SD and TGR(ASrAOGEN) rats after treatment with telmisartan (8 mg•kg À1 ).</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>SD VEH</cell><cell>SD TEL</cell><cell></cell><cell></cell><cell></cell><cell>TG VEH</cell><cell>TG TEL</cell><cell>Two-way ANOVA P-values</cell></row><row><cell></cell><cell></cell><cell>(n = 15)</cell><cell cols="3">(n = 15)</cell><cell></cell><cell>(n = 17)</cell><cell>(n = 19)</cell><cell>Drug</cell><cell>Strain</cell></row><row><cell cols="2">Body weight at age 6</cell><cell>248 ± 7</cell><cell>251 ± 9</cell><cell></cell><cell></cell><cell></cell><cell>184 ± 7</cell><cell>185 ± 5</cell><cell>0.7770</cell><cell>&lt;0.0001</cell></row><row><cell cols="2">Body weight gain (g)</cell><cell>414 ± 22</cell><cell>309 ± 11</cell><cell cols="2">*</cell><cell></cell><cell>212 ± 5</cell><cell>178 ± 5</cell><cell>&lt;0.0001</cell><cell>&lt;0.0001</cell></row><row><cell>BMI (kg • m</cell><cell>À2 )</cell><cell>7.98 ± 0.23</cell><cell cols="3">7.16 ± 0.15</cell><cell>*</cell><cell>6.10 ± 0.07</cell><cell>5.75 ± 0.09</cell><cell>0.0001</cell><cell>&lt;0.0001</cell></row><row><cell cols="2">Subcutaneous fat volume (mL)</cell><cell>47.5 ± 7.3</cell><cell cols="2">32.2 ± 2.9</cell><cell>*</cell><cell></cell><cell>16.3 ± 1.1</cell><cell>11.6 ± 0.7</cell><cell>0.0039</cell><cell>0.0039</cell></row><row><cell cols="2">Visceral fat volume (mL)</cell><cell>86.3 ± 11.3</cell><cell cols="2">58.8 ± 3.6</cell><cell>*</cell><cell></cell><cell>31.4 ± 1.7</cell><cell>21.9 ± 0.8</cell><cell>0.0004</cell><cell>&lt;0.0001</cell></row><row><cell cols="2">Femur length (mm)</cell><cell>40.9 ± 0.3</cell><cell cols="2">40.1 ± 0.4</cell><cell>*</cell><cell></cell><cell>38.8 ± 0.2</cell><cell>38.4 ± 0.2</cell><cell>0.0075</cell><cell>&lt;0.0001</cell></row><row><cell cols="2">Body length (vm)</cell><cell>28.4 ± 0.2</cell><cell cols="2">27.9 ± 0.2</cell><cell></cell><cell></cell><cell>25.5 ± 0.1</cell><cell>24.9 ± 0.2</cell><cell>0.0009</cell><cell>&lt;0.0001</cell></row><row><cell>Girth (cm)</cell><cell></cell><cell>22.3 ± 0.7</cell><cell cols="2">20.3 ± 0.3</cell><cell>*</cell><cell></cell><cell>18.1 ± 0.2</cell><cell>16.9 ± 0.3</cell><cell>0.0006</cell><cell>&lt;0.0001</cell></row><row><cell cols="2">Left ventricle (g)</cell><cell>1.19 ± 0.04</cell><cell cols="3">0.94 ± 0.04</cell><cell>*</cell><cell>1.04 ± 0.01</cell><cell>0.77 ± 0.02</cell><cell>*</cell><cell>&lt;0.0001</cell><cell>&lt;0.0001</cell></row><row><cell>Liver (g)</cell><cell></cell><cell>18.6 ± 0.9</cell><cell cols="2">17.2 ± 1.0</cell><cell></cell><cell></cell><cell>11.8 ± 0.3</cell><cell>10.4 ± 0.2</cell><cell>0.0312</cell><cell>&lt;0.0001</cell></row><row><cell>Kidneys (g)</cell><cell></cell><cell>1.76 ± 0.5</cell><cell cols="3">1.78 ± 0.06</cell><cell></cell><cell>1.11 ± 0.02</cell><cell>1.13 ± 0.02</cell><cell>0.7207</cell><cell>&lt;0.0001</cell></row><row><cell cols="2">Adrenal glands (mg)</cell><cell>28.3 ± 1.6</cell><cell cols="2">26.5 ± 0.8</cell><cell></cell><cell></cell><cell>25.4 ± 0.6</cell><cell>23.7 ± 0.2</cell><cell>0.0280</cell><cell>0.0004</cell></row></table><note><p><s>Data shown are means ± SEM.</s><s>Control rats received vehicle.</s><s>* P &lt; 0.05, significantly different from corresponding vehicle-treated rats after Bonferroni's post hoc test.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY<ref type="bibr" target="#b56">(Pawson et al., 2014)</ref> and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16<ref type="bibr" target="#b0">(Alexander et al., 2015)</ref>.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal ofPharmacology (2016) 173 1602-1617 1603</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal ofPharmacology (2016) 173 1602-1617 1605</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal ofPharmacology (2016) 173 1602-1617 1607</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal ofPharmacology (2016) 173 1602-1617 1609</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal ofPharmacology (2016) 173 1602-1617 1611</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal ofPharmacology (2016) 173 1602-1617 1613</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal ofPharmacology (2016) 173 1602-1617 1615</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal of Pharmacology (2016) 173 1602-1617 1617 act test).</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The authors gratefully acknowledge Martin Michel (Boehringer  Ingelheim Pharmaceuticals, Inc., Ingelheim, Germany)  for his critical reading of the manuscript and his helpful comments and Sherryl Sundell for improving the English style.</s></p><p><s>This study was supported by a grant from the Konrad Adenauer Stiftung (Germany).</s><s>W. R. received telmisartan from Boehringer Ingelheim Pharmaceuticals, Inc. (Ingelheim, Germany).</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author contributions</head><p><s>M.W., J.S., I.S., F .M.V ., J.B., C.T., M.B. and W.R. performed the research; W.R., M.W. and M.B. designed the research study.</s><s>W.R. and M.W. analysed the data, and W.R., M.W. and M.B. wrote the paper.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head><p><s>The authors declare no conflicts of interest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Declaration of transparency and scientific rigour</head><p><s>This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research recommended by funding agencies, publishers and other organizations engaged with supporting research.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting Information</head><p><s>Additional Supporting Information may be found in the online version of this article at the publisher's web-site: http://dx.doi.org/10.1111/bph.13461</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure S1</head><p><s>Plasma adiponectin levels of SD and TGR (AsOGEN) (=TG) rats before (A) or after (C, P diet 2-way ANOVA &lt;-0.0001)</s><s>CD feeding.</s><s>Plasma adiponectin of CD-fed SD rats and TGR(AsOGEN) rats before (B) or after (D, P drug 2-way ANOVA -= 0.014) TEL treatment.</s><s>Means and upper and lower quartiles are shown as boxplots.</s><s>Whiskers indicate variability between the 10 th and 90 th percentile.</s><s>Group sizes (given in the figures) are lower than indicated in Methods since we did not obtain blood from all animals before start.</s><s>*P &lt; 0.05 vs. appropriate control-fed rats after Bonferroni's post hoc test.</s><s>Figure <ref type="figure">S2</ref> Typical MRI images obtained by transverse T1weighted turbo spin-echo MRI of (A) SD and TGR(AsOGEN) (=TG) rats, which were fed with chow or CD or of (B) CDfed SD and TGR(AsOGEN) (=TG) rats, which were treated with telmisartan (TEL) or vehicle (VEH).</s><s>The abundance of visceral (F) and subcutaneous (G) fat deposits was quantified by computer-assisted planimetry and the results are shown in Tables <ref type="table">1, 2</ref>. Figure <ref type="figure">S3</ref> Histological findings of livers from control or CDfed SD and TGR(AsOGEN)(=TG) rats (upper panel; P diet 2-way ANOVA &lt; 0.003) and of CD-fed animals with respect to TEL treatment (lower panel).</s><s>Tissue specimens were evaluated in a blinded manner based on and scored for hepatocytes with steatosis.</s><s>Means and upper and lower quartiles are shown as boxplots.</s><s>Whiskers indicate variability between the 10 th and 90 th percentile.</s><s>Group sizes (given in the figures) are lower than indicated in Methods because of unexpected deaths of few rats during the study and technical problems, * P &lt; 0.05 vs. appropriate control-fed rats after Bonferroni's post hoc test.</s><s>Figure <ref type="figure">S4</ref> Energy expenditure (EE), respiratory ratio (RER), locomotion, and energy intake during indirect calorimetry measurements of (A) SD and TGR(AsOGEN) (=TG) rats, which were fed with chow or CD or of (B) CD-fed SD rats and TGR(AsOGEN) (=TG) rats which were treated with telmisartan (TEL) or vehicle (VEH).</s><s>Animals were housed for 3 days in calorimetry cages, but only the data from the 3 RD day are shown.</s><s>Mean values during light and dark periods for EE, RER, and locomotion as well as total energy intake are shown in Figures <ref type="figure">2 and ,</ref> respectively considering light and dark periods.</s><s>Figure <ref type="figure">S5</ref> A: Correlation between plasma leptin concentrations and energy intake at week 12 of SD rats and TGR (AsOGEN) (=TG) rats when fed with standard chow or CD; B: Correlation between plasma leptin and energy intake at week 12 of SD rats and TGR(AsOGEN) rats when fed with CD and simultaneously treated with telmisartan (TEL) or vehicle (VEH).</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The Concise Guide to PHARMACOLOGY 2015/16: G Protein-Coupled Receptors</title>
		<author>
			<persName><forename type="first">Sph</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Davenport</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Marrion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Benson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="5744" to="5869" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Triglycerides induce leptin resistance at the blood-brain barrier</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Banks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Coon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moinuddin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Shultz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nakaoke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="1253" to="1260" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Birkenfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">I</forename><surname>Shulman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="713" to="723" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Regional astrogliosis in the mouse hypothalamus in response to obesity</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Buckman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Ellacott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Comp Neurol</title>
		<imprint>
			<biblScope unit="volume">521</biblScope>
			<biblScope unit="page" from="1322" to="1333" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat</title>
		<author>
			<persName><forename type="first">A</forename><surname>Cabassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Coghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Govoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Barouhiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Speroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cavazzini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="2888" to="2897" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Cole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Nadler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Nunemaker</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">V alsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice</title>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="715" to="721" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Experimental design and analysis and their reporting: new guidance for publication in BJP</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Spina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ahluwalia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Giembycz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="3461" to="3471" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Davisson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Oliverio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Coffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Sigmund</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Divergent functions of angiotensin II receptor isoforms in the brain</title>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="103" to="106" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Central angiotensin II has catabolic action at white and brown adipose tissue</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>De Kloet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Foster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Herman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Sakai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">301</biblScope>
			<biblScope unit="page" from="E1081" to="E1091" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>De Souza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Araujo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bordin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ashimine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Zollner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Boschero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="page" from="4192" to="4199" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion</title>
		<author>
			<persName><forename type="first">V</forename><surname>Emilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cawthorne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Morton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Davenport</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="313" to="316" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Weight loss and the renin-angiotensin-aldosterone system</title>
		<author>
			<persName><forename type="first">S</forename><surname>Engeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bohnke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gorzelniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Janke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bader</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="356" to="362" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Fleegal-Demotta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Doghu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Banks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cereb Blood Flow Metab</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="640" to="647" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Cardiovascular phenotype of mice lacking all three subtypes of angiotensin II receptors</title>
		<author>
			<persName><forename type="first">F</forename><surname>Gembardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Heringer-Walther</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Van Esch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sterner-Kock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Le</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">F ASEB J</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="3068" to="3077" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Adiponectin: probe of the molecular paradigm associating diabetes and obesity</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ghoshal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bhattacharyya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Diabetes</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="151" to="166" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats</title>
		<author>
			<persName><forename type="first">P</forename><surname>Gohlke</surname></persName>
		</author>
		<author>
			<persName><surname>Ks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jurgensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Rascher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Culman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="909" to="918" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats</title>
		<author>
			<persName><forename type="first">P</forename><surname>Gohlke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wienen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stangier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Rascher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">298</biblScope>
			<biblScope unit="page" from="62" to="70" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Low glial angiotensinogen improves body habitus, diastolic function, and exercise tolerance in aging male rats</title>
		<author>
			<persName><forename type="first">L</forename><surname>Groban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Machado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Trask</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Kritchevsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Ferrario</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Endocrinol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="49" to="58" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Long-term blood pressure telemetry in AT2 receptor-disrupted mice</title>
		<author>
			<persName><forename type="first">V</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Milia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Plehm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Inagami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Luft</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="955" to="961" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Role of angiotensin II type 1 receptor in angiotensin II-induced cytokine production in macrophages</title>
		<author>
			<persName><forename type="first">F</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">X</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Interferon Cytokine Res</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="351" to="361" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone</title>
		<author>
			<persName><forename type="first">A</forename><surname>Harte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mcternan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Chetty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Coppack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="1954" to="1961" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-dependent pathways</title>
		<author>
			<persName><forename type="first">H</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Feng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="869" to="879" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice</title>
		<author>
			<persName><forename type="first">L</forename><surname>Hein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Barsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Pratt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Dzau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Kobilka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="page" from="744" to="747" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Angiotensin receptors in the brain</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hohle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Blume</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lebrun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Culman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Unger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Toxicol</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="306" to="315" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Obesity induces functional astrocytic leptin receptors in hypothalamus</title>
		<author>
			<persName><forename type="first">H</forename><surname>Hsuchou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Kastin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Markadakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Rogers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="889" to="902" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ichiki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P A</forename><surname>Labosky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Shiota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Okuyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Imagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fogo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="page" from="748" to="750" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">AT1A, AT1B, and AT2 angiotensin II receptor subtype gene expression in rat brain</title>
		<author>
			<persName><forename type="first">O</forename><surname>Jöhren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Inagami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Saavedra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="2549" to="2552" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Impaired blood-brain barrier function in angiotensinogen-deficient mice</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kakinuma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sugiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yagami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Goto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Murakami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="1078" to="1080" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Growth, metabolism, and blood pressure disturbances during aging in transgenic rats with altered brain renin-angiotensin systems</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Kasper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Ferrario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ganten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Ferder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Sonntag</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Physiol Genomics</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="311" to="317" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Animal research: reporting in vivo experiments: the ARRIVE guidelines</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kilkenny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Browne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Cuthill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Emerson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="page" from="1577" to="1579" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">U</forename><surname>Kintscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bramlage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Paar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Thoenes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Unger</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients</title>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Diabetol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">12</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Inhibiting angiotensin type 1 receptors as a target for diabetes</title>
		<author>
			<persName><forename type="first">U</forename><surname>Kintscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Foryst-Ludwig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Unger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Ther Targets</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1257" to="1263" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation</title>
		<author>
			<persName><forename type="first">F</forename><surname>Massiera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bloch-Faure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ceiler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Murakami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fukamizu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Gasc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">F ASEB J</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="2727" to="2729" />
			<date type="published" when="2001">2001a</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity</title>
		<author>
			<persName><forename type="first">F</forename><surname>Massiera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Seydoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Geloen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Quignard-Boulange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Turban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Saint-Marc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="5220" to="5225" />
			<date type="published" when="2001">2001b</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Mcgrath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lilley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="3189" to="3193" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists 1</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Michel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Foster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Brunner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Rev</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="809" to="848" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Overfeeding-induced obesity in spontaneously hypertensive rats: an animal model of the human metabolic syndrome</title>
		<author>
			<persName><forename type="first">A</forename><surname>Miesel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Thermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Heidbreder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dominiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Raasch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Nutr Metab</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="127" to="142" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than singledrug treatments in obese rats</title>
		<author>
			<persName><forename type="first">A</forename><surname>Miesel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Müller-Fielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Jöhren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Raasch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="2721" to="2735" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Monti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schinke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Böhm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ganten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bricca</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Glial angiotensinogen regulates brain angiotensin II receptors in transgenic rats TGR(ASrAOGEN)</title>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Regul Integr Comp Physiol</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="page" from="R233" to="R240" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Leptin impairs metabolic actions of insulin in isolated rat adipocytes</title>
		<author>
			<persName><forename type="first">G</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ertl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Preibisch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">272</biblScope>
			<biblScope unit="page" from="10585" to="10593" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Stress sensitivity is increased in transgenic rats with low brain angiotensinogen</title>
		<author>
			<persName><forename type="first">H</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kröger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Jöhren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Szymczak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dominiak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Endocrinol</title>
		<imprint>
			<biblScope unit="volume">204</biblScope>
			<biblScope unit="page" from="85" to="92" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Schweitzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Jöhren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dominiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Raasch</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Angiotensin II stimulates the reactivity of the pituitary-adrenal axis in leptin-resistant Zucker rats, thereby influencing the glucose utilization</title>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">293</biblScope>
			<biblScope unit="page" from="E802" to="E810" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Chronic blockade of angiotensin AT(1) receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats</title>
		<author>
			<persName><forename type="first">H</forename><surname>Müller-Fielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hübel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mildner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Barkhausen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Raasch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="page" from="746" to="760" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PP ARgamma target gene regulation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Müller-Fielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Landolt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Heidbreder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Werth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Jöhren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="1103" to="1115" />
			<date type="published" when="2012">2012a</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Preventing leptin resistance by blocking angiotensin II AT1 receptors in diet-induced obese rats</title>
		<author>
			<persName><forename type="first">H</forename><surname>Müller-Fielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Geissler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Winkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Raasch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="857" to="868" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Blood Pressure Response to Angiotensin II is Enhanced in Obese Zucker Rats and is Attributed to an Aldosterone-Dependent Mechanism</title>
		<author>
			<persName><forename type="first">H</forename><surname>Müller-Fielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Jöhren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Stellmacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwaninger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Raasch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="2417" to="2429" />
			<date type="published" when="2012">2012b</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure</title>
		<author>
			<persName><forename type="first">H</forename><surname>Müller-Fielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Markert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wittmershaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pahlke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Jöhren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Raasch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Naunyn Schmiedebergs Arch Pharmacol</title>
		<imprint>
			<biblScope unit="volume">383</biblScope>
			<biblScope unit="page" from="373" to="384" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Angiotensin II impairs glucose utilization in obese Zucker rats by increasing HP A activity via an adrenal-dependent mechanism</title>
		<author>
			<persName><forename type="first">H</forename><surname>Müller-Fielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Raasch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Horm Metab Res</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="173" to="180" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Angiotensin II type 2 receptor signaling affects dopamine levels in the brain and prevents binge eating disorder</title>
		<author>
			<persName><forename type="first">H</forename><surname>Nakaoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mogi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kan-No</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tsukuda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ohshima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Renin Angiotensin Aldosterone Syst</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="749" to="757" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Telmisartan suppresses food intake in mice via the melanocortin pathway</title>
		<author>
			<persName><forename type="first">K</forename><surname>Noma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Toshinaia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Koshinaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nakazato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Obes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="e93" to="e100" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer&apos;s disease model</title>
		<author>
			<persName><forename type="first">B</forename><surname>Ongali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Nicolakakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">K</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Aboulkassim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Papadopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rosa-Neto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurobiol Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="126" to="136" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Pawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Sharman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Benson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Faccenda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sph</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">P</forename><surname>Buneman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="D1098" to="D1106" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Rats with low brain angiotensinogen levels are protected against development of diet-induced obesity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Piehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schuchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Stölting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Raasch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Naunyn Schmiedebergs Arch Pharmacol</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page">S75</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Angiotensin II inhibition reduces stress sensitivity of hypothalamo-pituitary-adrenal axis in spontaneously hypertensive rats</title>
		<author>
			<persName><forename type="first">W</forename><surname>Raasch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wittmershaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dendorfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pahlke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dodt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="3539" to="3546" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<monogr>
		<title level="m" type="main">Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Braga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Mario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Porto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Rodrigues-Machado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Murari</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010">2010</date>
			<biblScope unit="page" from="1" to="7" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Arterioscler Thromb V asc Biol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="953" to="961" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Fernandes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Mario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A V</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Porto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Alvarez-Leite</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="340" to="347" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schinke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Baltatu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Böhm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Rascher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bricca</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="3975" to="3980" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Prevention of weight gain after AT1 receptor blockade in diet-induced rat obesity is at least partially related to an angiotensin (1-7)/Mas-dependent mechanism</title>
		<author>
			<persName><forename type="first">J</forename><surname>Schuchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Winkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Stölting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schuster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Barkhausen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="3764" to="3778" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schupp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Clemenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gineste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Witt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Janke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Helleboid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="3442" to="3452" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Adaptive immunity in obesity and insulin resistance</title>
		<author>
			<persName><forename type="first">H</forename><surname>Sell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Habich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Eckel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Endocrinol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="709" to="716" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Mitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rosenthal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Delafontaine</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting</title>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="451" to="458" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Protein phosphatase 2C-alpha knockdown reduces angiotensin II-mediated skeletal muscle wasting via restoration of mitochondrial recycling and function</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Tabony</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sukhanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Delafontaine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Skelet Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">20</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Angiotensinogen-deficient mice with hypotension</title>
		<author>
			<persName><forename type="first">K</forename><surname>Tanimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sugiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Goto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ishida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Takimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yagami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">269</biblScope>
			<biblScope unit="page" from="31334" to="31337" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Astrogliosis in the brain of obese Zucker rat: a model of metabolic syndrome</title>
		<author>
			<persName><forename type="first">D</forename><surname>Tomassoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Nwankwo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Gabrielli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Muhammad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Lokhandwala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">543</biblScope>
			<biblScope unit="page" from="136" to="141" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Angiotensin receptormediated oxidative stress is associated with impaired cardiac redox signaling and mitochondrial function in insulin-resistant rats</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>V Azquez-Medina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Popovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Thorwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sonanez-Organis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Heart Circ Physiol</title>
		<imprint>
			<biblScope unit="volume">305</biblScope>
			<biblScope unit="page" from="H599" to="H607" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Rapid total body fat measurement by magnetic resonance imaging: quantification and topography</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>V Ogt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ruehm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hunold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>De Greiff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nuefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Barkhausen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rofo</title>
		<imprint>
			<biblScope unit="volume">179</biblScope>
			<biblScope unit="page" from="480" to="486" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Coculture with primary visceral rat adipocytes from control but not streptozotocininduced diabetic animals increases glucose uptake in rat skeletal muscle cells: role of adiponectin</title>
		<author>
			<persName><forename type="first">V</forename><surname>Vu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sweeney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="4411" to="4419" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Weight loss after chronic AT1-receptor blockade can be attributed to a central mechanism</title>
		<author>
			<persName><forename type="first">M</forename><surname>Winkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schuchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Stölting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Raasch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Naunyn Schmiedebergs Arch Pharmacol</title>
		<imprint>
			<biblScope unit="volume">388</biblScope>
			<biblScope unit="page">S26</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from dietinduced obesity and insulin resistance</title>
		<author>
			<persName><forename type="first">L</forename><surname>Yvan-Charvet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Even</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bloch-Faure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guerre-Millo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Moustaid-Moussa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="991" to="999" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue</title>
		<author>
			<persName><forename type="first">L</forename><surname>Yvan-Charvet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Massiera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lamande</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ailhaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Teboul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Moustaid-Moussa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="1421" to="1428" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Delafontaine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Garcia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="604" to="612" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PP ARgamma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Zorad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Dou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Benicky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hutanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tybitanclova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">552</biblScope>
			<biblScope unit="page" from="112" to="122" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
